Fiona Elwood, Ph.D., VP and Neurodegeneration Disease Area Stronghold (DAS) Leader at Janssen, the pharmaceutical companies of J&J.

Fiona has extensive experience in neuroscience and neurodegenerative research and development, a passion for bringing relief to patients and their caregivers, and dedication to scientific excellence and exceptional teamwork. She brings deep expertise in molecular mechanisms of neurodegeneration, drug discovery and development. In her current role as the neurodegeneration disease area stronghold leader at Janssen, she is responsible for the scientific strategy of the neurodegeneration portfolio from target selection through Phase III clinical development. Previously, she was the Interim Global Head of Neuroscience and Head of Neurodegeneration at Novartis Institute for Biomedical Research, responsible for a portfolio of drug discovery programs. Before Novartis, she spent nearly 10 years at Merck Research Laboratories in positions of increasing responsibility in both neuroscience and immunology therapeutic areas.

Fiona received her doctorate in Neuroscience from the University of London, UK where she developed novel mouse models of Alzheimer’s disease and Familial British Dementia, and subsequently completed her postdoctoral work on autophagy in Alzheimer’s disease at Stanford University.

Fiona received her doctorate in Neuroscience from the University of London, UK where she developed novel mouse models of Alzheimer’s disease and Familial British Dementia, and subsequently completed her postdoctoral work on autophagy in Alzheimer’s disease at Stanford University.